NEUROTYPE INC.

Cue-induced drug craving monitoring for opioid use disorder with visual evoked potentials

NEUROTYPE INC. is active in the national institute on drug abuse space based in MINNEAPOLIS, MN, founded in 2019.

Profile

Project Summary / Abstract
More than 2 million people in the United States have an Opioid Use Disorder (OUD). Overall, at least half of
the treatment-seeking population relapse, contributing to over 75,000 overdose deaths annually. The purpose
of this SBIR Fast-Track application is to create a regulated device to objectively monitor Cue-Induced Craving
(CIC) in Opioid Use Disorder (OUD) patients. CIC, which is caused by environmental triggers, is a major factor
in OUD drug use and relapse but currently, there are no standard tools to measure it. The NeuromarkR™
software interfaces with electroencephalogram (EEG) systems to quantify the extent to which Event-Related
Potential (ERP) brain responses elicited by opioid cues (e.g., image containing a pill bottle) resemble brain
responses elicited by naturally appetitive cues (e.g., palatable foods). The Phase I specific aims include
integrating NeuromarkR™ with a highly portable and usable EEG system that is already cleared by the Food
and Drug Administration (FDA), and conducting clinical usability and bench testing. The Phase II specific aims
include evaluating a CIC Neuro-Affective Profile (CIC-NAP) with respect to opioid craving and other OUD
outcomes through clinical trials. Of central focus, the CIC-NAP biomarker will be evaluated by its prediction of
clinical outcomes such as recent and prospective drug use, among other varia

As a business in national institute on drug abuse, NEUROTYPE INC. is listed here with the public details available about it.

MINNEAPOLIS, MN is where the company is located.

Its current recorded stage is SBIR/STTR.

Recorded headcount: c_00001_00010 employees.

Total disclosed funding stands at about $87K.

Website: www.neurotype.io